Theratechnologies (TSE:TH) has released an update.
Theratechnologies has announced a potential early 2025 supply disruption for EGRIFTA SV due to a voluntary shutdown at their contract manufacturer’s facility, following FDA inspection. The company is working with the FDA to resume production and mitigate patient impact, with a projected revenue shortfall of US$1.6 million for the fiscal year 2024.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
